Longboard Pharmaceuticals, Inc. financial data

Symbol
LBPH on Nasdaq
Industry
Pharmaceutical Preparations
Location
4275 Executive Square, Suite 950, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.78K % +94.5%
Return On Equity -36.9 % +50.7%
Return On Assets -34.5 % +48.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.9M shares +69.3%
Common Stock, Shares, Outstanding 33.6M shares +63.5%
Entity Public Float 148M USD +185%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 38.9M shares +69.3%
Weighted Average Number of Shares Outstanding, Diluted 38.9M shares +69.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 56.3M USD +42%
General and Administrative Expense 16.6M USD +43.7%
Operating Income (Loss) -72.9M USD -42.4%
Net Income (Loss) Attributable to Parent -64.7M USD -31.1%
Earnings Per Share, Basic -2.16 USD/shares +15%
Earnings Per Share, Diluted -2.16 USD/shares +15%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.6M USD -25.1%
Cash, Cash Equivalents, and Short-term Investments 305M USD +384%
Assets, Current 309M USD +371%
Other Long-term Investments 244K USD +597%
Property, Plant and Equipment, Net 1K USD -85.7%
Operating Lease, Right-of-Use Asset 3.86M USD +554%
Assets 313M USD +373%
Accounts Payable, Current 2.48M USD +27.6%
Accrued Liabilities, Current 551K USD -1.43%
Liabilities, Current 14.7M USD +86.5%
Operating Lease, Liability, Noncurrent 3.57M USD +1567%
Accumulated Other Comprehensive Income (Loss), Net of Tax -475K USD -63.8%
Retained Earnings (Accumulated Deficit) -177M USD -57.5%
Stockholders' Equity Attributable to Parent 295M USD +407%
Liabilities and Equity 313M USD +373%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.2M USD -15.9%
Net Cash Provided by (Used in) Financing Activities 286M USD +1241%
Net Cash Provided by (Used in) Investing Activities -231M USD -3896%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 33.6M shares +63.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 40.3M USD +181%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.8M USD -23.9%
Deferred Tax Assets, Valuation Allowance 31M USD +70%
Cash and Cash Equivalents, Period Increase (Decrease) -31.3M USD -148%
Deferred Tax Assets, Gross 31.1M USD +69.1%
Operating Lease, Liability 3.86M USD +556%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.9M USD -32.8%
Lessee, Operating Lease, Liability, to be Paid 5.24M USD +728%
Operating Lease, Liability, Current 294K USD -21.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 785K USD +83.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 662K USD +225%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.37M USD +3093%
Lessee, Operating Lease, Liability, to be Paid, Year Three 820K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.15M USD +63%
Lessee, Operating Lease, Liability, to be Paid, Year Four 856K USD
Operating Lease, Payments 105K USD +11.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 31M USD +70%
Share-based Payment Arrangement, Expense 6.27M USD +114%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%